AR108568A2 - MUTANTS OF FGF21 AND USES OF THE SAME - Google Patents
MUTANTS OF FGF21 AND USES OF THE SAMEInfo
- Publication number
- AR108568A2 AR108568A2 ARP170101344A ARP170101344A AR108568A2 AR 108568 A2 AR108568 A2 AR 108568A2 AR P170101344 A ARP170101344 A AR P170101344A AR P170101344 A ARP170101344 A AR P170101344A AR 108568 A2 AR108568 A2 AR 108568A2
- Authority
- AR
- Argentina
- Prior art keywords
- substitution
- amino acid
- pharmaceutical composition
- fgf21
- mutants
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Un polipéptido aislado que comprende una secuencia de aminoácido de SEC ID Nº 4 y además comprende: (a) al menos una sustitución de aminoácido en la posición 180; y (b) al menos una sustitución de aminoácido seleccionada del grupo que consta de: (i) una sustitución en la posición 171; y (ii) una sustitución en la posición 98; y (c) combinaciones de las mismas. Reivindicación 11: Una composición farmacéutica que comprende el polipéptido aislado de la reivindicación 2 y un agente de formulación farmacéuticamente aceptable. Reivindicación 13: Un método de tratamiento de un trastorno metabólico que comprende la administración a un paciente humano que lo necesite de la composición farmacéutica de la reivindicación 12. Reivindicación 17: El ácido nucleico aislado de la reivindicación 16, en donde el ácido nucleico comprende SEC ID Nº 46.Claim 1: An isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 4 and further comprising: (a) at least one amino acid substitution at position 180; and (b) at least one amino acid substitution selected from the group consisting of: (i) a substitution at position 171; and (ii) a substitution in position 98; and (c) combinations thereof. Claim 11: A pharmaceutical composition comprising the isolated polypeptide of claim 2 and a pharmaceutically acceptable formulation agent. Claim 13: A method of treating a metabolic disorder comprising administration to a human patient in need of the pharmaceutical composition of claim 12. Claim 17: The isolated nucleic acid of claim 16, wherein the nucleic acid comprises SEC ID No. 46.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17573609P | 2009-05-05 | 2009-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108568A2 true AR108568A2 (en) | 2018-09-05 |
Family
ID=52988550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101344A AR108568A2 (en) | 2009-05-05 | 2017-05-18 | MUTANTS OF FGF21 AND USES OF THE SAME |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR108568A2 (en) |
TN (1) | TN2011000553A1 (en) |
UA (1) | UA107458C2 (en) |
-
2010
- 2010-05-04 UA UAA201114397A patent/UA107458C2/en unknown
-
2011
- 2011-10-31 TN TNP2011000553A patent/TN2011000553A1/en unknown
-
2017
- 2017-05-18 AR ARP170101344A patent/AR108568A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
TN2011000553A1 (en) | 2013-05-24 |
UA107458C2 (en) | 2015-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2661500T3 (en) | HMGB1 variants and their uses | |
CY1119140T1 (en) | COMPOSITION COMPOSITIONS AND METHODS OF CONSTRUCTION AND USE | |
RU2018119765A (en) | INJECTION DRUGS BASED ON BOTULOTOXIN AND METHODS OF THEIR APPLICATION, PROVIDING LONG-TERM THERAPEUTIC AND COSMETIC ACTION | |
MX2017004592A (en) | Pharmaceutical formulations for the oral delivery of peptide or protein drugs. | |
WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
BR112014028633A8 (en) | amd treatment using aav sflt-1 | |
NO20100301L (en) | Improved brimonidine compositions for the treatment of erythema | |
CO6640331A2 (en) | Anti-aging skin treatment | |
BRPI1007379B8 (en) | pharmaceutical compositions for the treatment or prevention of oral infections by e. coli | |
ES2682670T3 (en) | Streptococcus bacteriophage lysines for the detection and treatment of gram positive bacteria | |
BRPI0815578B8 (en) | CDCA1 PEPTIDE, ITS USE AND IMMUNOGENIC COMPOSITION INCLUDING THE SAME TO INDUCE IMMUNITY, TREAT AND/OR PREVENT CANCER, AS WELL AS IN VITRO METHOD TO INDUCE AN ANTIGEN-PRESENTING CELL AND A CYTOTOXIC T-CELL (KILLER) | |
AR112166A1 (en) | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B | |
NZ599930A (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
RU2020121540A (en) | INJECTABLE BOTULINIC TOXIN COMPOSITIONS AND METHODS OF THEIR APPLICATION WITH HIGH RESPONSE RATES AND LONG DURATION OF EFFECT | |
EP4349359A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
RU2015116264A (en) | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN PATIENTS WITH DIABETES | |
AR068020A1 (en) | COMBINED THERAPY FOR PANCREAS CANCER USING AN ANTIGEN PEPTIDE AND A CHEMOTHERAPEUTIC AGENT | |
SA519410993B1 (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
CL2021000550A1 (en) | Tumor associated peptide (tumap); nucleic acid; expression vector; recombinant host cell comprising the peptide; method of producing the peptide; pharmaceutical composition; use to prepare a drug useful for treating cancer; pharmaceutical kit (divisional application no. 201900460) | |
BR112014017141A2 (en) | method of treating diabetes using unglycosylated apolipoprotein a-iv | |
AR095076A1 (en) | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE | |
AR093908A1 (en) | FUSION OF HUMAN AND ALBUMINE GROWTH HORMONE, FORMULATION AND USES OF THE SAME | |
AR105752A1 (en) | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
RU2016137292A (en) | FGF-18 COMPOUND DIAGRAM | |
AR093476A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |